The US Food and Drug Administration (FDA) recently approved Eli Lilly and Company’s (NYSE:LLY) radioactive diagnostic agent, Amyvid (florbetapir F 18 Injection). Amyvid has been designed to help detect the density of beta-amyloid plaques in patients (with cognitive impairment) who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.
While a negative scan would mean little to no amyloid plaques are present, a positive scan would point towards the presence of moderate … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards